Home Blog Page 1124

Guoen Technology Advances Toward Dual Listing with Hong Kong IPO, Sets Final Offer Price at HK$36

By
Advertorial Desk
-

HONG KONG, Feb. 3, 2026 /PRNewswire/ — On January 15, Qingdao Guoen Technology Co., Ltd. (SHE: 002768) announced that it has successfully passed the hearing of the Hong Kong Stock Exchange (HKEX) Main Board, marking a significant milestone in its pursuit of a dual listing on both the Shenzhen and Hong Kong stock exchanges. The company’s H-share initial public offering (IPO) will be exclusively sponsored by China Merchants Securities International.

According to the updated prospectus and official announcement dated February 3, Guoen Technology has finalized the issue price of its H-shares at HK$36.00 per share, excluding relevant fees. A total of 30 million shares will be offered globally—3 million for the Hong Kong public offering and 27 million for international placement, with an over-allotment (greenshoe) option available. The Hong Kong public offering period ran from January 27 to January 30. Trading of the H-shares is scheduled to commence on February 4, 2026, on the HKEX Main Board.

This IPO is expected to raise capital primarily for the development of domestic and overseas manufacturing bases, as well as to supplement working capital—supporting the company’s long-term goal of building a cross-market, globally integrated supply platform.

Founded in Qingdao, Guoen Technology is a leading player in the advanced polymer materials sector. The company operates a vertically integrated platform covering the entire value chain of high-performance plastics—from raw material polymerization to modification, compounding, and the manufacturing of end-use products. Its product portfolio spans modified plastics, composite materials, and biodegradable polymers, with strong applications in sectors such as new energy vehicles, smart manufacturing, consumer electronics, and healthcare.

Notably, Guoen is accelerating investment into strategic materials such as PEEK (polyether ether ketone), a high-performance engineering thermoplastic widely used in aerospace, medical devices, and robotics. The company has announced plans to establish 1,000-ton annual PEEK production capacity, positioning itself at the forefront of domestic innovation and import substitution in this field.

This is a critical step for Guoen Technology to deepen capital market access, enhance international brand recognition, and advance its ambition to become a global materials technology platform.

The Year Strategy Meets Scale: Brillio’s Beyond the Curve 2026 Charts the Enterprise AI Roadmap

By
Advertorial Desk
-

DALLAS, Feb. 3, 2026 /PRNewswire/ — Brillio today unveiled Beyond the Curve 2026, a flagship outlook that reframes the AI agenda for enterprise leaders and shows how to convert scattered pilots into measurable value at scale. Anchored by ADAM (Agentic Data and Application Management), Brillio’s AI accelerator platform, the company brings a practical view on building autonomous, governed, and scalable AI foundations. The report argues that the decisive advantage now lies with companies that address Strategy, Technology, and AI Native Talent as a single operating system for growth.

Behind the curve infographic
Behind the curve infographic

Over the past year, AI has moved from early-stage experimentation to active, everyday application. The question is no longer if AI will transform the enterprise, but how fast leaders can seed value across the P&L. Beyond the Curve 2026 distills what separates winners from the pack: outcome first strategy, platform centric integration, and a talent model built for AI assisted engineering, so AI is not a tool that is simply deployed but a capability that is fully operationalized. 

“Executives don’t need another AI hype cycle; they need a way to seamlessly integrate AI into their business operations,” stated Chander Damodaran, CTO, Brillio. “This report encapsulates the trends we observe with our customers. By aligning strategy, platforms, and AI-native talent, agentic systems start to perform tasks rather than just offering advice, marking the point where productivity and resilience significantly improve.” 

What’s inside Beyond the Curve 2026 

  • A new operating narrative for AI: This section explains why treating AI as an enterprise capability instead of treating it as a collection of isolated projects leads to stronger outcomes, clearer governance, and faster execution. 
  • Four Key Business Priorities for Leaders: Four key priorities drive resilience and growth this year: Cost optimization, digital transformation, customer experience, and new business models. Investing in scalable revenue streams will build resilience and drive sustainable growth. 
  • Talent as the multiplier: This section describes how AI assisted engineering, copilots, multi agent development frameworks, and large-scale reskilling help organizations close delivery gaps and maintain innovation velocity. 
  • Sector playbooks: The report shows how Agentic AI is transforming industries including BFSI, Hi Tech, Healthcare, Life Sciences, Retail and CPG, and Communications, Media and Telecom by shifting from task level automation to outcome driven autonomy. Banks are using it for fraud detection and compliance, Hi Tech firms for accelerating software engineering, and Healthcare and Life Sciences organizations for clinical triage, trial matching, and safety monitoring. Retail and CPG companies are applying it to demand forecasting, supply chain optimization, and store level execution, while Communications and Media providers are improving network planning, service operations, and customer support. Across all sectors, Agentic AI enables real-time decision intelligence and operational performance that delivers measurable business results. 

Why it matters now 

The report emphasizes the need for organizations to move beyond isolated AI experiments and adopt integrated, outcome-driven approaches. By aligning AI initiatives with strategic priorities, organizations can accelerate decision-making, streamline operations, and deliver personalized customer experiences at scale. 

Brillio’s positioning: Built to Accelerate. Engineered to Deliver. 

Brillio positions itself as The Enterprise AI Accelerator, reaffirming its ethos to accelerate impact, from AI intention to scaled execution. ADAM, Brillio’s AI accelerator platform connects data, digital, and AI ecosystems to make every platform intelligent, every workflow agentic, and every outcome measurable. ADAM delivers proven architectures and accelerators while ensuring clients retain full ownership, governance, and compliance control. By unifying industry-aligned context with scalable execution, ADAM connects AI agents seamlessly across enterprise ecosystems to orchestrate end-to-end business transformation. 

Know more about ADAM: https://www.brillio.com/the-enterprise-ai-accelerator/agentic-data-and-application-management/ 

Beyond the Curve 2026 is designed as a board‑to‑shop‑floor guide for leaders’ intent on turning AI from promise to performance. Click here to read or download the full report to explore the insights shaping enterprise AI in 2026. 

About Brillio: 

Brillio is The Enterprise AI Accelerator helping Fortune 1000 companies move from AI ambition to scaled impact, faster. Powered by our AI accelerator platform – Agentic Data and Application Management (ADAM), Brillio is one of the fastest-growing digital technology service providers, delivering transformation across five core workstreams: business-led transformation, customer experience transformation, AI and data engineering, digital engineering, and infrastructure engineering.

With 14 delivery locations across North America, Europe, and Asia and a team of over 6,000 customer-obsessed professionals, Brillio combines deep industry expertise, modern engineering, and accelerators to deliver measurable outcomes. Learn more at www.Brillio.com

 

 

Elevated Materials Completes First Year with Strong Commercial Momentum and Announces Plans to Triple Production in 2026

By
Advertorial Desk
-

Company delivers more than 100 kilometers to one of its customers and accelerates toward gigawatt-hour scale manufacturing

SANTA CLARA, Calif., Feb. 3, 2026 /PRNewswire/ — Elevated Materials today announced major milestones as it celebrates its one-year anniversary, highlighting rapid growth in production, customer adoption, and organizational scale. Elevated Materials was carved out of Applied Materials on February 1, 2025, with an investment from the TPG Rise Climate Fund.

The company closed 2025 with record output of ultra-thin lithium metal films, shipping product to more than 30 customers worldwide. Notably, Elevated Materials delivered more than 100 kilometers of lithium film to a single customer, underscoring strong market demand for high-quality, scalable lithium metal solutions.

“The industry has long been seeking a reliable source of high-quality, ultra-thin lithium films to improve battery performance,” said Jim Cushing, CEO of Elevated Materials. “We are filling that gap with our ultra-thin, smooth, and low-defect ELi™ films. Demand has been particularly strong for lithium metal anodes, where ELi significantly improves both safety and performance.”

Elevated Materials’ proprietary roll-to-roll vacuum deposition platforms produce ELi, the industry’s highest-quality ultra-thin lithium metal films. These films enable next-generation anode architectures across electric vehicles, consumer electronics, aviation, and grid-scale energy storage.

The company’s production momentum reflects the growing urgency among battery manufacturers to secure reliable supplies of ultra-thin lithium metal anodes as advanced cell designs move closer to commercial deployment.

Looking ahead, Elevated Materials noted that 2026 will be focused on scaling production to meet increasing customer demand.

“As we move into 2026, Elevated Materials will continue ramping to true gigawatt-hour scale manufacturing,” Cushing added. “With accelerating customer demand, we are tripling production capacity to support the commercial battery programs of our key customers.”

Elevated Materials’ successful first year and rapid scale-up reinforce its position as a critical supplier for next-generation battery developers seeking consistent, scalable lithium metal solutions.

About Elevated Materials
Elevated Materials is a TPG Rise Climate portfolio company carved out of Applied Materials and focused on scaling breakthrough battery technologies to accelerate global decarbonization and electrification. The company draws on decades of expertise in semiconductors and roll-to-roll vacuum deposition to deliver the industry’s widest and highest-quality ultra-thin lithium films. Elevated’s films boost energy density, extend battery life, and enable significantly faster charging across lithium-ion battery applications and anode chemistries.

CIMG Inc. announced the signing of computing power equipment sales contracts totaling approximately $2 million

By
Advertorial Desk
-

HONG KONG, Feb. 3, 2026 /PRNewswire/ — CIMG Inc. (“CIMG” or the “Company”) (Nasdaq: IMG), a business group specializing in digital health and sales development, which utilizes technologies and marketing networks to enhance its business partners’ sales growth and commercial value, today announced that its subsidiary, Beijing Xinmiao Shidai Technology Development Co., Ltd. has entered into five sales contracts for computing power hardware equipment with multiple companies, including Guangzhou Liangjingjing Technology Co., Ltd., Tianjin Herunsheng Technology Development Co., Ltd., Tianjin Weixinda Technology Co., Ltd., and Tianjin Lanhai Interaction Technology Co., Ltd., which contracts were executed between December 2025 and January 2026. The total contract value, including taxes, amounts to approximately $2 million.

The products covered by these contracts include two main categories, computing servers and power electronic components, and are intended for customers such as cloud service providers and industrial enterprises. These contracts reflect the Company’s continued expansion in the core hardware segment of the computing power infrastructure industry and are expected to contribute to the Company’s financial performance and operating results in 2026.

Alice Wang, Chairperson of the Board and Chief Executive Officer of CIMG Inc., stated, “With the industrial deployment of large-scale models and the deepening of the China ‘East Data West Computing; strategy, computing power has evolved from a basic resource into a strategic asset comparable to semiconductors and energy. Our continued focus on the artificial intelligence computing power sector is intended to support long-term customer resources and strengthen our competitive positioning.”

“Currently, the Company is focused on developing ‘scenario-based computing power solutions.’ To address the varying technical needs and budget constraints of different clients, the Company provides end-to-end services, including hardware configuration, equipment installation and debugging, optimization and after-sales support, aimed at addressing compatibility issues in traditional computing power procurement. The Company expects to continue expanding its business in the computing power facility services sector, leveraging innovative business models to capture opportunities arising from the global AI industry development,” added Alice Wang.

About CIMG

CIMG is a business group specializing in digital health and sales development, with a cryptocurrency-focused strategy. The Company leverages AI and cryptocurrencies (such as Bitcoin and stablecoins) to drive business growth, helping clients maximize user growth and enhance brand management value. The Company’s current client portfolio includes brands such as Kangduoyuan, Maca-Noni, Qianmao, Huomao, and Coco-mango.

Forward-Looking Statements

This press release contains information about the Company’s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks related to the execution, timing, and realization of supply and sales contracts, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary for its operations, and its ability to protect its intellectual property. The Company encourages you to review other factors that may affect its future results in its Annual Reports, Quarterly Reports, registration statements, and other filings with the Securities and Exchange Commission.

Captiva Verde Launches First Public Use Atmospheric Water Stations

By
Advertorial Desk
-
Jacksonville, Florida – Newsfile Corp. – February 3, 2026 – Captiva Verde Wellness Corp. (CSE: PWR) (OTC Pink: CPIVF) (the “Company or Captiva”) announces the launch of the first public use, sustainable real estate based, Atmospheric Water Stations, in collaboration with Wisconsin-based manufacturer, Origen, and the University of Northern Florida – Center for Utility Security and Resiliency. There were over 60 attendees including leadership representing the food and hospitality industry, federal, state, municipal government, military and academia. Water Bankruptcy is a global crisis affecting food security, personal health, sustainability and resiliency. Greater than 70% of American water is toxic, 100’s of times more-so than the safe limits, with most bottled water failing the same standards, unable to remove “forever chemicals,” heavy-metals, and other hazardous elements, only recently discovered to have adverse health consequences. Global brands have had to shut down their supplies because they are simply no longer drinkable. This $9 trillion annual threat can only be ameliorated through novel means, which Captiva Verde has seized upon: until now, cost effective and practical solutions have been elusive. This all changes today. This launch event also marks the start of Origen’s partnership with Captiva Verde, through which Captiva will distribute Origen’s Atmospheric Water Generators across institutional, commercial, and government markets. Together, the teams are focused on making on-site water generation accessible in regions where traditional systems are costly, unreliable, or simply unavailable. The Origen equipment is unique and fully patent protected, superior not only in quality to all competitors, but in the Madison Industries-backed manufacturing capabilities.

https://origenawg.com/blog/origens-wellspring-awg-to-officially-launch-january-30/

Our large (10,000+ gpd), Captiva Verde water stations, to be constructed across Florida, cost a fraction of traditional infrastructure upgrades. This will create a new economy, a new industry, new jobs, and deliver pure water that is both “plastic free” and produced “on location,” rather than being shipped for hundreds of miles. Our Origen stations are where sustainability meets purity. And there is no more favorable location than Florida, where population density [23M and growing], affordable energy, citizen-friendly government, temperatures, and humidity converge to make for the most blessed location in America to harvest our airborne aquifer.

On Behalf of the Board of Directors

“Jeff Ciachurski”

Jeffrey Ciachurski
Executive Chairman and Director
Cell: (949) 903-5906
E-mail: westernwind@shaw.ca

Neither the Canadian Securities Exchange nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward Looking Information: This news release includes “forward-looking statements” and “forward-looking information” within the meaning of Canadian securities laws and United States securities laws (together, “forward-looking statements”). All statements included in this news release, other than statements of historical fact, are forward-looking statements including, without limitation, statements with respect to the expansion of Captiva’s health and wellness platform. Forward-looking statements include predictions, projections and forecasts and are often, but not always, identified by the use of words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, “potential”, “target”, “budget”, “propose” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions and includes the negatives thereof. Forward-looking statements are based on a number of assumptions and estimates that, while considered reasonable by management based on the business and markets in which the Company operates, are inherently subject to significant operational, economic, and competitive uncertainties, risks and contingencies. These include assumptions regarding, among other things: general business and economic conditions. There can be no assurance that forward-looking statements will prove to be accurate and actual results, and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include those described under the heading “Risks and Uncertainties” in the Company’s most recently filed MD&A (a copy of which is available under the Company’s SEDAR profile at www.sedarplus.ca). The Company does not undertake to update or revise any forward-looking statements, except in accordance with applicable law.

The issuer is solely responsible for the content of this announcement.

Fab Educators Summit 2026: Innovation from China — Integrating Maker Culture and AI & STEM to Advance Educational Equity

By
Advertorial Desk
-

SHANGHAI, Feb. 3, 2026 /PRNewswire/ — On January 30, 2026, the Fab Educators Summit successfully brought together innovators and practitioners from 19 countries to explore how digital fabrication and artificial intelligence (AI) technologies are transforming education. 54 speakers shared practical insights, challenges, and classroom projects online, supporting a global audience of educators from 79 countries.

During the summit’s eduFAB online seminar, case studies presented by two leading Chinese innovators demonstrated distinct yet complementary pathways for leveraging technology to advance educational equity.

Fab Educators Summit 2026: Innovation from China
Fab Educators Summit 2026: Innovation from China

Mushroom Cloud Makerspace: Expanding Rural Access to AI & STEM Education Through Maker Education

Rebecca Jiang, Operations Manager of Mushroom Cloud Makerspace—a leading FabLab hub in China—presented a talk titled “Empowering Rural Students Growth Through Long-term Collaboration.” She detailed a field-tested partnership with Spring Organization Public Welfare, a youth-focused NGO. Their collaboration has successfully introduced AI and STEM education to K–12 schools in rural regions, including Guizhou and Yunnan, using a replicable co-building framework. This model focuses on creating inquiry-based learning spaces, developing project-based maker curricula, and providing low-barrier tools that transform advanced technology into accessible creative media. From 2023 to 2025, the program delivered over 11 major activities, reached 10 schools and more than 1,000 students, and mobilized 12 volunteer mentors, providing sustained support across multiple provinces over several years.

A key component of this collaboration is Mushroom Cloud Makerspace’s support for Spring Organization’s ETS Conference, a decade-old public welfare initiative for rural students. Since 2022, volunteer experts from Mushroom Cloud Makerspace have been integral to integrating AI and STEM contents into the conference. Building on the long-term partnership established between both parties, and through the adoption of easy-to-use programming platforms and hands-on hardware tools, structured AI and STEM courses have now been extended to more rural schools, ushering in a new phase of sustainable impact.

DFRobot’s ‘Ski Adventure’ AI Workshop: Training AI Models Through Creative Activities

Jiaman Li, Senior Technical Trainer at AI-driven STEM education solutions provider DFRobot, led a popular 45-minute online workshop titled “Training AI Models Through Creative Activities.” Using the “Ski Adventure” pose-recognition game as the core activity, participants were guided through the complete process of building their own motion-sensing interactive system step by step. Centered on pose recognition technology, learners used the MindPlus V2.0 programming platform to go through the full development cycle—from defining skiing movement categories and collecting personal pose data via camera (suggesting 150-200 image samples per category, while the software displayed real-time collection counts), to training a personalized classification model and deploying it for real-time game control.

A key highlight was the workshop’s data-driven design philosophy: participants continuously improved model performance by refining the quality and diversity of their datasets, gaining an intuitive understanding of how data shapes AI behavior. With MindPlus V2.0 programming platform supporting self-trained models, the workshop turned abstract AI concepts into an accessible, hands-on, and highly teachable learning experience. Ethical considerations, including algorithmic fairness and data privacy, were embedded throughout the session; for instance, learners examined inclusivity challenges by observing how recognition accuracy can vary across different body types and age groups when using the same model. Ultimately, the workshop went beyond technical skills, turning AI into a tangible, reflective, and responsible creative practice.

The Fab Educators Summit 2026 showed the successful Chinese models from its eduFAB workshop. It demonstrated that sustained collaboration among maker spaces, EdTech firms, and public partners can effectively integrate AI/SETM/Maker Culture into classrooms even in the rural places worldwide. These tools foster student creativity, problem-solving, and responsible tech awareness in real-world contexts.

Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501

By
Advertorial Desk
-

Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone payment of USD 5 million from Menarini Group after first-in-patient dosing in a Phase 1 trial of MEN2501, highly differentiated small molecule KIF18A inhibitor in development for chromosomally unstable solid tumors designed using Insilico’s generative AI engine.

CAMBRIDGE, Mass., Feb. 3, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”), a clinical-stage, generative artificial intelligence (AI)-driven biotechnology company, today announced that it has received USD 5 million from Menarini Group (“Menarini”) as an additional milestone payment, following the completion of first-in-patient dosing in a Phase 1 study of MEN2501, which was licensed to Menarini in January 2025. MEN2501 (previously known as ISM9682) is a highly differentiated small molecule inhibitor of kinesin KIF18A motor protein with potent activity in cancers with chromosome instability.  

As part of a strategic collaboration to accelerate the development and delivery of transformative cancer therapies, the asset was subsequently licensed to Stemline Therapeutics, Inc. (“Stemline”), a wholly owned subsidiary of the Menarini Group, with the combined value of the agreements exceeding USD 550 million. Pursuant to the partnership, both parties actively advanced the program transition and subsequent development activities. Following IND approval for this program, Insilico received the first development and regulatory milestone payment of USD 3 million in July 2025.

“The program rapidly advanced into a Phase I clinical trial and successfully completed first patient dosing, fully demonstrating Menarini and Stemline’s exceptional agility and clinical expertise,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “This milestone shows our shared commitment to delivering innovative therapies for cancer treatment. We are proud to further strengthen our partnership and encouraged to see AI-discovered drug candidates reaching such a critical stage, bringing us closer to providing novel treatment options for patients worldwide.”

“Getting the first patient dosed in our MEN2501 Phase 1 study is a meaningful milestone that underscores how quickly promising science can move forward through focused clinical execution,” said Elcin Barker Ergun, CEO of the Menarini Group. “We value our partnership with Insilico as we translate AI-enabled discovery into clinical programs, with the goal of bringing new, transformational treatment options to patients facing aggressive cancers.”

The collaboration between Insilico and Menarini has continued to expand since its inception. Prior to MEN2501, in January 2024, Insilico announced that it entered into an exclusive global license collaboration with Menarini for MEN2312, a novel KAT6 inhibitor for breast cancer and other oncology indications, with the combined value of the agreements exceeding USD 500 million. The MEN2312 program has progressed smoothly into clinical development, and Insilico has received early development milestone payments.

In addition to the collaboration pipelines, Insilico has extensive experience in AI-driven oncology, drug discovery and development. The company has established a robust oncology pipeline that targets multiple cancer indications, leveraging both moderately novel and well-established mechanisms. Among its most promising assets, the potential best-in-class pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412 are both undergoing global, multicenter Phase I clinical trials.

Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting a benchmark for AI-driven drug R&D. While traditional early-stage drug discovery typically requires an average of 4.5 years, Insilico has nominated 20 preclinical candidates from 2021 to 2024, with an average timeline—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program. 

About Insilico Medicine 

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com

Metabolon Names Andrew Messick Chief Financial Officer

By
Advertorial Desk
-

Seasoned life sciences finance leader brings deep expertise in operational excellence and M&A to support Metabolon’s next stage of growth

MORRISVILLE, N.C., Feb. 3, 2026 /PRNewswire/ — Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, announces the appointment of Andrew (Drew) Messick as Chief Financial Officer.

“Drew brings more than 25 years of financial leadership experience, with a proven track record of driving growth through financial and operational excellence in the life sciences sector.  His expertise will be invaluable as Metabolon continues to scale and execute on its strategic objectives,” said Rohan Hastie, Ph.D., President and CEO of Metabolon. “Drew’s appointment further strengthens Metabolon’s executive leadership team as we expand our capabilities and market presence.”

Drew is an accomplished finance executive with over a decade of experience leading finance and operations for privately held life sciences companies. Over his career, he has served as Chief Financial Officer for multiple organizations, building high-performing teams, optimizing financial and operational processes, and successfully navigating mergers and acquisitions.

Drew is a graduate of the University of North Carolina at Chapel Hill, where he earned a Bachelor of Science in Business Administration and a Master of Accounting from UNC’s Kenan-Flagler Business School. He is both a Chartered Financial Analyst (CFA) and a Certified Public Accountant (CPA). Drew resides in Cary, North Carolina, with his wife and three children.

“Metabolon’s scientific leadership and differentiated multiomics capabilities position the company for long-term success,” said Andrew Messick, Chief Financial Officer. “I’m excited to join the team and look forward to supporting Metabolon’s continued growth through disciplined financial management and operational rigor.”

For more information about Metabolon’s services, please visit:

About Metabolon
Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other ‘omics’ technologies.  With 25 years of experience, 15,000+ client projects, 4,000+ scientific publication references, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques.  Metabolon’s Global Discovery Panel is powered by the world’s largest proprietary metabolomics reference library.  Metabolon’s industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, that support customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.

About Metabolomics
Metabolomics, the large-scale study of all small molecules in a biological system, is the only omics technology that provides a complete current-state functional readout of a biological system.  Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic and external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers, enabling a better understanding of a drug’s mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.

1...1,1231,1241,125...6,479Page 1,124 of 6,479